tm logo
LINROLUX
REGISTERED

on 06 Nov 2020

Last Applicant/ Owned by

BRISTOL-MYERS SQUIBB COMPANY (A DELAWARE CORPORATION)

Route 206 & Province Line RoadPrinceton, NJ 08543

US

Serial Number

1916568 filed on 24th Aug 2018

Registration Number

TMA1087218 registered on 06th Nov 2020

Registration expiry Date

06th Nov 2030

Correspondent Address

SUITE 16001 FIRST CANADIAN PLACE100 KING STREET WESTTORONTO

ONTARIO

CA

M5X1G5

LINROLUX

Trademark usage description

pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, heart failure, thrombosi Read More

Classification Information


Class [005]
Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, heart failure, thrombosis, stroke, cancer, respiratory diseases, auto-immune diseases, rheumatoid arthritis, lupus, inflammatory bowel disease, solid organ transplant rejection, hepatitis, fibrosis, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disorders, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; pharmaceutical preparations for human use, namely, immunotherapies for the treatment of cancer; pharmaceutical preparations for human use for the treatment and prevention of metabolic disorders, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, anti-inflammatories, anti-infectives, central nervous system depressants, central nervous system stimulants, anti-psychotics, cytokine inhibitory drugs; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for the treatment of cancer, respiratory diseases, auto-immune diseases, and for the prevention and treatment of solid organ transplant rejection; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti-infectives, and for use as anti-inflammatories; diagnostic pharmaceutical preparations for human use for increasing the heart rate and for use as medical imaging contrast agents; pharmaceutical preparations for human use that modulate the immune system; pharmaceutical and biological preparations for human use, namely, immunotherapies; pharmaceutical preparations for human use, namely, cells for medical or clinical use; pharmaceutical preparations for human use, namely, T-cells for medical purposes for the treatment of cancer and auto-immune diseases; diagnostic pharmaceutical preparations for human use, namely, diagnostic kits consisting primarily of cells for medical laboratory use; pharmaceutical preparations for human use, namely, kits comprised of cells and pharmaceuticals for medical or clinical use for the treatment of cancer and autoimmune diseases;


Classification kind code

11

Mark Details


Serial Number

1916568

Mark Type

Trademark

Legal History


Show more

Action TakenStatus
Submitted for opposition 190
on 04th Nov 2020
Registration Pending
Submitted for opposition 42
on 12th Aug 2020
Advertised
Submitted for opposition 26
on 16th Jul 2020
Approved
Submitted for opposition 27
on 16th Jul 2020
Approval Notice Sent
Submitted for opposition 22
on 13th Dec 2019
Search Recorded
Submitted for opposition 20
on 13th Dec 2019
Examiner's First Report
Submitted for opposition 135
on 15th Feb 2019
Amendment to Application
Submitted for opposition 31
on 31st Aug 2018
Formalized
Submitted for opposition 30
on 24th Aug 2018
Filed
Submitted for opposition 1
on 24th Aug 2018
Created